Metraipolis › archive › dc_f869aef7e64a

Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options — Europe PMC PMID:41294710

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41294710
DOI
10.3390/curroncol32110648
License (as archived)
solo-consultazione
Archived
2026-11-08T09:26:01.623Z
SHA-256 of the archived text
953c45cd96b9519cbef86769e84b33a6f14ae04f72c20862c0b60ba4ebbffa5c
Stable URL of this page
https://metraipolis.com/documento/dc_f869aef7e64a

How to cite

Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options — Europe PMC PMID:41294710 — Europe PMC (en), https://europepmc.org/article/MED/41294710 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f869aef7e64a (Metraipolis archive dc_f869aef7e64a, sha256 953c45cd96b9519cbef86769e84b33a6f14ae04f72c20862c0b60ba4ebbffa5c)
BibTeX
@misc{dcf869aef7e64a,
  title = {Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options — Europe PMC PMID:41294710},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41294710},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f869aef7e64a; sha256 953c45cd96b9519cbef86769e84b33a6f14ae04f72c20862c0b60ba4ebbffa5c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41294710. Agents can read the archived copy with the MCP tool read_document.